Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
about
A design for phase I trials in completely or partially ordered groups.Boron's journey: advances in the study and application of pharmacokinetics.Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.Bortezomib in mantle cell lymphoma: comparative therapeutic outcomesBortezomib for the treatment of non-Hodgkin's lymphomaEffect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I StudiesPharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.Current strategies for treatment of relapsed/refractory multiple myeloma.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range.Isotonic designs for phase I trials in partially ordered groups.
P2860
Q30252706-208E17CF-9EB4-4D0C-9195-847343B8D981Q30394591-74918D35-3D38-48E2-A0F1-6B5A9D436DAAQ31050273-73DFA1A6-4C81-4ADB-AD82-608C53982979Q33409681-BBFD26EC-6F88-4755-8EE7-FC1BCD6F880CQ33874209-73587146-2523-4D84-81B0-382053EBA7DCQ34788381-82A6BB35-5E73-4762-A738-283BBD3AE097Q36204764-0103D213-B34D-4D60-ACFE-7F0A6152CCB3Q36278006-6D452C96-4150-43FF-9831-37EE2F0E69CDQ36868056-9A85D584-3642-4A49-9D82-AB145726124EQ37166427-4EC10294-83B7-4FC0-9A01-9F6B80E1524AQ37327280-84DA40D4-1A79-4DF6-8425-387855FED871Q38182683-249E3AEA-1E16-48F4-9DD4-CCA7F9B0ACB1Q38287050-56EC631F-5E43-49D0-9161-D7C7D292CEE6Q38538693-47F1979C-32DD-4C7D-B2E3-ED39352D903AQ38832181-35F00C6D-7BFB-40E9-B610-C0C01A41B1BFQ45064728-FCD41320-FA45-4DC1-A367-A471CC6FAB95
P2860
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Dose-escalating and pharmacolo ...... ysfunction Working Group Study
@ast
Dose-escalating and pharmacolo ...... ysfunction Working Group Study
@en
type
label
Dose-escalating and pharmacolo ...... ysfunction Working Group Study
@ast
Dose-escalating and pharmacolo ...... ysfunction Working Group Study
@en
prefLabel
Dose-escalating and pharmacolo ...... ysfunction Working Group Study
@ast
Dose-escalating and pharmacolo ...... ysfunction Working Group Study
@en
P2093
P2860
P1476
Dose-escalating and pharmacolo ...... ysfunction Working Group Study
@en
P2093
Angela Davies
Anne Hamilton
Chris H Takimoto
Daniel Mulkerin
James Mier
John J Wright
John Sarantopoulos
Karthik Venkatakrishnan
Lisa von Moltke
Merrill J Egorin
P2860
P2888
P304
P356
10.1007/S00280-011-1637-5
P577
2011-04-09T00:00:00Z